Zimbus Breezhaler


indacaterol / glycopyrronium / mometasone furoate

This medicine is authorised for use in the European Union.


Zimbus Breezhaler is an asthma medicine for inhalation. It is used for maintenance (regular) treatment in adults whose asthma is not controlled well enough with inhaled long-acting beta-2 agonist together with a high dose of an inhaled corticosteroid. It should be used for patients who have had at least one asthma attack (exacerbations) in the last year.

Zimbus Breezhaler contains the active substances indacaterol, glycopyrronium bromide and mometasone.

This EPAR was last updated on 09/12/2021

Authorisation details

Product details
Zimbus Breezhaler
Agency product number
Active substance
  • Glycopyrronium bromide
  • Indacaterol (acetate)
  • Mometasone furoate
International non-proprietary name (INN) or common name
  • indacaterol
  • glycopyrronium
  • mometasone furoate
Therapeutic area (MeSH)
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Novartis Europharm Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Vista Building
Elm Park
Merrion Road
Dublin 4

Product information

12/11/2021 Zimbus Breezhaler - EMEA/H/C/005518 - IB/0009/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Maintenance treatment of asthma in adults whose disease is not adequately controlled.

Assessment history

Related content

How useful was this page?

Add your rating
1 rating